Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%

    Perrigo Confirms First to File Patent Challenge for Generic Version of
                            Testosterone Gel 1.62%

PR Newswire

ALLEGAN, Mich., Feb. 19, 2013

ALLEGAN, Mich., Feb. 19, 2013 /PRNewswire/ --Perrigo Company (Nasdaq: PRGO;
TASE) announced that it has filed with the U.S. Food and Drug Administration
(FDA) an Abbreviated New Drug Application for testosterone gel 1.62% and that
it has notified AbbVie Inc., the owner of the Reference Listed Drug of its

(Logo: )

On February 15, 2013, the Unimed Pharmaceuticals subsidiary of AbbVie and
Besins Healthcare filed suit against Perrigo in the United States District
Court for the District of Delaware, alleging patent infringement.This action
formally initiates the process under the Hatch-Waxman Act.Perrigo believes
that it is a first filer for this opportunity, entitling it to 180 days of
generic exclusivity.

Androgel® 1.62% (testosterone gel 1.62%) is indicated to treat males who have
low or no testosterone. Annual sales were approximately $680 million annually,
as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another
example of our investment in new products and continued focus on bringing
extended topicals to market. As always, Perrigo is committed to making quality
healthcare more affordable for our customers and consumers."

Previously, on November 2, 2011, Perrigo announced that it filed with the FDA
a New Drug Application for testosterone gel 1.0% and that it notified Abbott
Products Inc., the owner of the Reference Listed Drug of its filing

From its beginnings as a packager of generic home remedies in 1887, Allegan,
Michigan-based Perrigo Company has grown to become a leading global provider
of quality, affordable healthcare products. Perrigo develops, manufactures and
distributes over-the-counter (OTC) and generic prescription (Rx)
pharmaceuticals, infant formulas, nutritional products, pet health, dietary
supplements and active pharmaceutical ingredients (API). The Company is the
world's largest manufacturer of OTC pharmaceutical products for the store
brand market. The Company's primary markets and locations of logistics
operations have evolved over the years to include the United States, Israel,
Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the
Internet (

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2012, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709,; Bradley Joseph, Senior
Manager, Investor Relations and Communication, +1-269-686-3373,
Press spacebar to pause and continue. Press esc to stop.